Amrit Kaur Kaler, Consultant Molecular Pathology and Genomics Department of Genetics and Molecular Medicine at Kokilaben Dhirubhai Ambani Hospital, shared her and her collegues’ article published in the Journal of Precision Oncology on LinkedIn:
“Round table discussion on IDH inhibitors in Biliiary tract cancers.
The availability of Ivosedinib in Indian market will change the scenerio in the management. This also opens the door for screening of molecular biology of cancers at initial diagnosis and monitoring of tumor informed biomarkers for better management.
Quality of Next Generation testing (NGS) with standarized reporting using ASCO/ESMO/ACMG guidelines and specialized datasets and computational tools for analysis.
Thanks to organizers to let me be part of this scientific delight.”
More posts featuring GI Cancers.
